Last reviewed · How we verify

NCT04647734

The Protective Potential of Exercise Training on the Cardiopulmonary Morbidity After COVID-19

Completed NA Last updated 8 June 2022
What this trial tests

NA trial testing High intensity interval training in COVID-19, SARS-CoV2 in 28 participants. Completed in 10 February 2022.

Timeline
1 February 2021
Primary endpoint
1 February 2022
10 February 2022

Quick facts

Lead sponsorRigshospitalet, Denmark
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment28
Start date1 February 2021
Primary completion1 February 2022
Estimated completion10 February 2022
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

40 and older, any sex, with COVID-19, SARS-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

40 COVID-19 survivors that have been discharged from the hospital will be included in this investigator-blinded randomised study with a 12-week exercise intervention. Patients will be 1:1 block-randomised by sex to either a supervised high intensity interval-based exercise group or standard care (control group).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Protective potential of high-intensity interval training on cardiac structure and function after COVID-19: protocol and statistical analysis plan for an investigator-blinded randomised controlled trial.
    Rasmussen IE, Foged F, Bjørn Budde J, Rasmussen RS, et al · · 2021 · cited 2× · PMID 34794987 · DOI 10.1136/bmjopen-2020-048281

Verify or expand the search:

Other trials of High intensity interval training

Trials testing the same drug.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04647734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing